+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Platform Market by Product Type, Therapeutic Area, End User - Global Forecast to 2030- Product Image
mRNA Platform Market by Product Type, Therapeutic Area, End User - Global Forecast to 2030- Product Image
Sale

mRNA Platform Market by Product Type, Therapeutic Area, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5460245
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA Platform Market grew from USD 16.33 billion in 2024 to USD 19.93 billion in 2025. It is expected to continue growing at a CAGR of 21.60%, reaching USD 52.83 billion by 2030.

Setting the Stage for mRNA Innovation

The accelerating evolution of messenger RNA (mRNA) technologies has ushered in a new era of therapeutic and diagnostic possibilities. Fueled by groundbreaking research and high-profile successes in vaccine development, the mRNA platform now stands at the intersection of scientific innovation and commercial potential. This introduction outlines the fundamental drivers reshaping the landscape, from rapid advances in lipid nanoparticle delivery systems to the maturation of synthesis and analytical tools.

As stakeholders across pharmaceuticals, biotechnology, and academic research intensify their focus on mRNA applications, understanding the broader market context becomes paramount. This section frames the critical forces at play-regulatory momentum favoring accelerated pathways, strategic partnerships bridging discovery and development, and mounting capital flows dedicated to next-generation therapeutics. By situating readers within this dynamic environment, the introduction establishes a foundation for the deeper analyses that follow, ensuring clarity around both opportunities and challenges inherent to the mRNA platform.

Emerging Forces Redefining mRNA Research

Over the past several years, transformative shifts have redefined mRNA research from theoretical curiosity to practical reality. Breakthroughs in nucleotide modification have dramatically improved stability and reduced immunogenicity, enabling repeated dosing regimens and broadening therapeutic horizons. Simultaneously, the optimization of lipid nanoparticle formulations has elevated delivery efficiency, unlocking new in vivo targeting capabilities across diverse tissue types.

Beyond technological refinements, collaborative ecosystems have emerged as central pillars of progress. Pharmaceutical innovators have forged alliances with academic institutions and specialized contract research organizations, accelerating the translation of mRNA into clinical candidates. Regulatory agencies have responded by adapting frameworks that balance rigorous safety assessments with the need for timely patient access. Moreover, investment patterns have shifted toward platform-based strategies that hedge risk across multiple indications, underscoring a collective belief in mRNA’s transformative potential.

Together, these converging forces signal a departure from incremental research toward a holistic, platform-driven paradigm. The result is a landscape defined by rapid iteration cycles, cross-disciplinary partnerships, and an unwavering focus on unlocking the next wave of mRNA-enabled breakthroughs.

Assessing the 2025 U.S. Tariff Ripple Effects

The imposition of updated United States tariffs in 2025 has introduced a new layer of complexity for mRNA supply chains. By increasing duties on raw materials and specialized reagents imported from key manufacturing hubs, these measures have ripple effects across procurement, pricing, and production timelines. Suppliers and end users alike are navigating revised cost structures that necessitate strategic adjustments to sourcing and inventory management.

In response, many organizations are exploring alternative supply routes and supplier diversification strategies to mitigate exposure. Some developers have accelerated investments in domestic manufacturing capabilities, aiming to reduce reliance on cross-border logistics. However, establishing new production lines entails significant time and capital commitments, raising potential bottlenecks in the near term.

Furthermore, the tariff-driven cost pressures underscore the importance of operational agility. Companies are reevaluating contractual terms, exploring long-term procurement agreements, and prioritizing relationships with integrated providers that can deliver end-to-end solutions. As the industry adapts, the overarching lesson is clear: tariff constraints demand proactive supply chain resilience measures to ensure continuity in the fast-paced realm of mRNA innovation.

Uncovering Depths through Strategic Segmentation

Strategic segmentation offers a nuanced lens for understanding key growth arenas and unmet needs across the mRNA ecosystem. When considering product type, the diagnostics segment encompasses both cancer-focused assays and infectious disease detection platforms, while drug discovery reagents span critical screening molecules alongside advanced transfection agents. Within research kits, specialized offerings range from lipid nanoparticle assembly tools to comprehensive mRNA synthesis modules. Therapeutics portfolios address cardiology applications, neurologic interventions, oncology treatments, and therapies for rare conditions. The vaccine category further divides into prophylactic and therapeutic modalities, each with distinct development pathways and market dynamics.

Shifting focus to therapeutic area, cardiovascular applications dissect into arrhythmia management and heart failure strategies, while the infectious disease domain tackles high-priority targets such as COVID-19, influenza, and rabies prevention. Neurologic research zeroes in on Alzheimer’s and Parkinson’s disease pathways, contrasted by oncology efforts directed at hematologic malignancies and solid tumor profiles. Rare disease initiatives concentrate on genetic disorder correction and metabolic disorder modulation, underscoring mRNA’s potential for precision medicine.

Examining end users reveals a diverse stakeholder landscape. Academic centers, including major colleges and universities, spearhead foundational research. Diagnostic labs, from hospital-based testing facilities to independent reference operations, drive assay deployment. Hospitals-public and private alike-integrate mRNA diagnostics and treatments into patient care. Pharmaceutical companies, both large-scale and smaller innovators, advance pipeline candidates. Research institutes, whether government-funded or privately operated, contribute specialized expertise and infrastructure.

Mapping Regional mRNA Market Nuances

Regional analysis illuminates how geographic factors shape mRNA development trajectories and commercial adoption. In the Americas, robust investment ecosystems and advanced biotech hubs have accelerated clinical translation, with significant contributions from both established pharmaceutical centers and agile biotech clusters. Regulatory frameworks in this region continue to evolve, fostering expedited review processes and public-private collaborations. Meanwhile, Europe, Middle East & Africa exhibit heterogeneous dynamics: Western Europe leads in platform innovation and early-stage trials, underpinned by strong academic-industry linkages, whereas emerging markets in the Middle East and Africa demonstrate growing interest in capacity building and technology transfer initiatives.

Moving to the Asia-Pacific region, rapid scaling of manufacturing infrastructure and government-supported biotech incubators have positioned several nations as key players in global supply chains. Regulatory harmonization efforts are underway to streamline cross-border clinical studies and product approvals. Together, these regional nuances underscore the importance of tailored market entry strategies and collaborative models that resonate with local scientific ecosystems and policy environments.

Profiling Leaders Shaping the mRNA Landscape

A focused examination of leading organizations reveals distinct strategic approaches that drive success within the mRNA domain. Some pioneers have built comprehensive platforms that integrate in-house lipid nanoparticle formulation, nucleotide synthesis, and analytical services, thereby accelerating internal workflows and reducing external dependencies. Other entities specialize in niche segments-such as high-throughput transfection reagents or advanced lipid excipients-leveraging deep technical know-how to supply larger ecosystem partners.

Collaboration strategies vary widely: global pharmaceutical leaders tend to initiate co-development partnerships with academic innovators or biotechnology startups to de-risk novel therapeutic concepts. In contrast, smaller companies often secure strategic alliances or licensing agreements that grant access to expanded distribution networks and regulatory expertise. Additionally, a subset of organizations invests heavily in proprietary delivery technologies, seeking to establish durable competitive barriers. Across the board, successful actors emphasize agility, scalable manufacturing, and integrated service models as foundational pillars for sustainable growth.

Driving Growth with Practical Industry Guidance

Industry frontrunners can harness actionable insights to maintain momentum and capitalize on emerging opportunities. First, embedding supply chain flexibility into strategic planning is critical: by cultivating multiple sourcing channels and establishing redundancy in material procurement, organizations insulate themselves from tariff shifts and cross-border disruptions. Second, fostering collaborative consortia with academic institutions and contract development providers accelerates pipeline progression and shares risk across partners. Third, investing in modular manufacturing platforms that accommodate diverse product types enables rapid scale-up and efficient resource utilization.

Moreover, prioritizing regulatory engagement-through early consultations and adaptive trial designs-streamlines approval pathways and enhances stakeholder alignment. Embracing data-driven decision making, particularly in formulation optimization and preclinical modeling, further sharpens development efficiency. Finally, advancing workforce capabilities in specialized areas such as nanoparticle engineering and mRNA analytics ensures that talent gaps do not impede innovation. By operationalizing these recommendations, leaders can solidify their positions and drive sustainable value creation.

Ensuring Rigor with Robust Research Methods

The research methodology underpinning this report combines primary and secondary approaches to deliver rigorous, actionable insights. Extensive interviews with subject matter experts-from formulation scientists and clinical investigators to regulatory advisors-provide first-hand perspectives on technological trends and market challenges. Complementing these dialogues, comprehensive literature reviews of peer-reviewed publications, patent filings, and regulatory filings ensure full visibility into the competitive landscape.

Quantitative validation is achieved through analysis of supply chain data, published financial reports, and transactional records, ensuring that qualitative observations align with real-world market dynamics. Peer benchmarking and case study analysis further contextualize best practices, while scenario mapping elucidates potential risk factors related to policy changes and technological breakthroughs. Together, this multi-faceted approach delivers a cohesive framework that balances depth of insight with methodological transparency.

Synthesizing Insights for Strategic Clarity

In summarizing the executive insights, several themes stand out. The confluence of technological maturation, regulatory adaptation, and strategic partnerships has elevated mRNA from a promising research area to a dynamic commercial frontier. While tariff introductions in 2025 introduce complex supply chain considerations, proactive resilience strategies can effectively mitigate their impact. Segmentation analysis underscores diverse value drivers across product types, therapeutic areas, and end-user categories, pointing to opportunities for specialization and platform integration.

Geographic nuances further shape market approaches, with distinct growth patterns in the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. Leading organizations demonstrate that integrated service models, scalable manufacturing, and targeted collaborations are foundational to accelerated pipeline progression. By synthesizing these insights, decision-makers gain a comprehensive vantage on optimizing investments, de-risking development pathways, and positioning their portfolios for sustained success in the evolving mRNA landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Diagnostics
      • Cancer
      • Infectious
    • Drug Discovery Reagents
      • Screening Reagents
      • Transfection Reagents
    • Research Kits
      • Lipid Nanoparticles
      • MRna Synthesis Kits
    • Therapeutics
      • Cardiology
      • Neurologic
      • Oncology
      • Rare Diseases
    • Vaccines
      • Prophylactic
      • Therapeutic
  • Therapeutic Area
    • Cardiology
      • Arrhythmia
      • Heart Failure
    • Infectious
      • COVID-19
      • Influenza
      • Rabies
    • Neurologic
      • Alzheimer’s
      • Parkinson’s
    • Oncology
      • Hematologic Malignancies
      • Solid Tumors
    • Rare Diseases
      • Genetic Disorders
      • Metabolic Disorders
  • End User
    • Academic Centers
      • Colleges
      • Universities
    • Diagnostic Labs
      • Hospital Labs
      • Reference Labs
    • Hospitals
      • Private
      • Public
    • Pharmaceutical Companies
      • Large
      • Small
    • Research Institutes
      • Government
      • Private
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Moderna, Inc.
  • BioNTech SE
  • CureVac SE
  • Arcturus Therapeutics Holdings, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Vaxart, Inc.
  • Gritstone bio, Inc.
  • Providence Therapeutics Holdings Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. mRNA Platform Market, by Product Type
8.1. Introduction
8.2. Diagnostics
8.2.1. Cancer
8.2.2. Infectious
8.3. Drug Discovery Reagents
8.3.1. Screening Reagents
8.3.2. Transfection Reagents
8.4. Research Kits
8.4.1. Lipid Nanoparticles
8.4.2. MRna Synthesis Kits
8.5. Therapeutics
8.5.1. Cardiology
8.5.2. Neurologic
8.5.3. Oncology
8.5.4. Rare Diseases
8.6. Vaccines
8.6.1. Prophylactic
8.6.2. Therapeutic
9. mRNA Platform Market, by Therapeutic Area
9.1. Introduction
9.2. Cardiology
9.2.1. Arrhythmia
9.2.2. Heart Failure
9.3. Infectious
9.3.1. COVID-19
9.3.2. Influenza
9.3.3. Rabies
9.4. Neurologic
9.4.1. Alzheimer’s
9.4.2. Parkinson’s
9.5. Oncology
9.5.1. Hematologic Malignancies
9.5.2. Solid Tumors
9.6. Rare Diseases
9.6.1. Genetic Disorders
9.6.2. Metabolic Disorders
10. mRNA Platform Market, by End User
10.1. Introduction
10.2. Academic Centers
10.2.1. Colleges
10.2.2. Universities
10.3. Diagnostic Labs
10.3.1. Hospital Labs
10.3.2. Reference Labs
10.4. Hospitals
10.4.1. Private
10.4.2. Public
10.5. Pharmaceutical Companies
10.5.1. Large
10.5.2. Small
10.6. Research Institutes
10.6.1. Government
10.6.2. Private
11. Americas mRNA Platform Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa mRNA Platform Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific mRNA Platform Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Moderna, Inc.
14.3.2. BioNTech SE
14.3.3. CureVac SE
14.3.4. Arcturus Therapeutics Holdings, Inc.
14.3.5. Pfizer Inc.
14.3.6. Sanofi S.A.
14.3.7. GlaxoSmithKline plc
14.3.8. Vaxart, Inc.
14.3.9. Gritstone bio, Inc.
14.3.10. Providence Therapeutics Holdings Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. MRNA PLATFORM MARKET MULTI-CURRENCY
FIGURE 2. MRNA PLATFORM MARKET MULTI-LANGUAGE
FIGURE 3. MRNA PLATFORM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY SCREENING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY TRANSFECTION REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA SYNTHESIS KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MRNA PLATFORM MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MRNA PLATFORM MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MRNA PLATFORM MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MRNA PLATFORM MARKET SIZE, BY COVID-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MRNA PLATFORM MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MRNA PLATFORM MARKET SIZE, BY ALZHEIMER’S, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MRNA PLATFORM MARKET SIZE, BY PARKINSON’S, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MRNA PLATFORM MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MRNA PLATFORM MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL MRNA PLATFORM MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL MRNA PLATFORM MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL MRNA PLATFORM MARKET SIZE, BY COLLEGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL MRNA PLATFORM MARKET SIZE, BY REFERENCE LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL MRNA PLATFORM MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL MRNA PLATFORM MARKET SIZE, BY LARGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL MRNA PLATFORM MARKET SIZE, BY SMALL, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL MRNA PLATFORM MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 110. CANADA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. CANADA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 112. CANADA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 113. CANADA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 114. CANADA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 115. CANADA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 116. CANADA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 117. CANADA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 118. CANADA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 119. CANADA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 120. CANADA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 121. CANADA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 122. CANADA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. CANADA MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 124. CANADA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 125. CANADA MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. CANADA MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 127. CANADA MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 128. MEXICO MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 130. MEXICO MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 134. MEXICO MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 135. MEXICO MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 136. MEXICO MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 138. MEXICO MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 139. MEXICO MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 140. MEXICO MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. MEXICO MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 143. MEXICO MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 145. MEXICO MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 176. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 212. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 219. GERMANY MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. GERMANY MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 221. GERMANY MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 222. GERMANY MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 223. GERMANY MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 224. GERMANY MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 225. GERMANY MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 226. GERMANY MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 227. GERMANY MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 228. GERMANY MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 229. GERMANY MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 230. GERMANY MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 231. GERMANY MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. GERMANY MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 234. GERMANY MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. GERMANY MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 236. GERMANY MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 237. FRANCE MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. FRANCE MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 239. FRANCE MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 240. FRANCE MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 241. FRANCE MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 242. FRANCE MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 243. FRANCE MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 244. FRANCE MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 245. FRANCE MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 247. FRANCE MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 248. FRANCE MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 249. FRANCE MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. FRANCE MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 251. FRANCE MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 252. FRANCE MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. FRANCE MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 254. FRANCE MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 273. ITALY MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. ITALY MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 275. ITALY MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 276. ITALY MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 277. ITALY MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 278. ITALY MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 279. ITALY MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 280. ITALY MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 281. ITALY MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 282. ITALY MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 283. ITALY MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 284. ITALY MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 285. ITALY MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. ITALY MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 287. ITALY MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 288. ITALY MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 289. ITALY MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 290. ITALY MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 291. SPAIN MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. SPAIN MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 293. SPAIN MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 294. SPAIN MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 295. SPAIN MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 296. SPAIN MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 297. SPAIN MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 298. SPAIN MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 299. SPAIN MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 300. SPAIN MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 301. SPAIN MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 302. SPAIN MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 303. SPAIN MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. SPAIN MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 305. SPAIN MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 306. SPAIN MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. SPAIN MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 308. SPAIN MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 330. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 332. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 334. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 336. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 338. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 342. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 344. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 345. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 346. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2030 (USD MILLION)
TABLE 348. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 350. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 352. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2030 (USD MILLION)
TABLE 354. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 356. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 358. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY ACADEMIC CENTERS, 2018-2030 (USD MILLION)
TABLE 359. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

The companies profiled in this mRNA Platform market report include:
  • Moderna, Inc.
  • BioNTech SE
  • CureVac SE
  • Arcturus Therapeutics Holdings, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Vaxart, Inc.
  • Gritstone bio, Inc.
  • Providence Therapeutics Holdings Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 19.93 Billion
Forecasted Market Value ( USD ) by 2030 $ 52.83 Billion
Compound Annual Growth Rate21.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, Distribution Channel - Global Forecast to 2030 - Product Image

mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, Distribution Channel - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
mRNA Platform - Global Strategic Business Report - Product Image

mRNA Platform - Global Strategic Business Report

  • Report
  • 334 Pages
  • Global
From
mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions - Product Image

mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions

  • Report
  • 343 Pages
  • Global
From
mRNA Vaccine and Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

mRNA Vaccine and Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.